Timing and durability of response to erenumab in patients with chronic migraine

BACKGROUND: Erenumab is a human anti‐calcitonin gene‐related peptide receptor monoclonal antibody approved for migraine prevention. We sought to further assess the temporal patterns of response to erenumab in patients with chronic migraine (CM), specifically the onset and sustainability of monthly m...

Descripción completa

Detalles Bibliográficos
Autores principales: Tepper, Stewart J., Lucas, Sylvia, Ashina, Messoud, Schwedt, Todd J., Ailani, Jessica, Scanlon, James, Klatt, Jan, Chou, Denise E., Wang, Andrea, Paiva da Silva Lima, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519048/
https://www.ncbi.nlm.nih.gov/pubmed/34363708
http://dx.doi.org/10.1111/head.14193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519048/
https://www.ncbi.nlm.nih.gov/pubmed/34363708
http://dx.doi.org/10.1111/head.14193

Ejemplares similares